Apotex and Intas Biopharmaceuticals extend their collaborative development of biosimilars to include pegfilgrastim

January 30, 2009 -- Apotex Inc. of Canada and Intas Biopharmaceuticals Limited of India have extended their business agreement to develop a biosimilar version of pegfilgrastim, a protein that is used to treat neutropenia (a side effect of cancer chemotherapy).

the details can be read here.